Literature DB >> 27999144

Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study.

Thomas G Cotter1, Kelli N Burger2, Mary E Devens3, Julie A Simonson3, Kari L Lowrie3, Russell I Heigh4, Douglas W Mahoney2, David H Johnson3, David A Ahlquist3, John B Kisiel5.   

Abstract

Background: Studies of colorectal cancer screening by multitarget stool DNA (MT-sDNA) show false-positive (FP) rates of 7% to 13%. It is unclear whether FP patients are at increased long-term risk of adverse outcomes.
Methods: We compared subsequent clinical events among patients with apparent FP MT-sDNA with those in patients reported as true negative (TN). This was a retrospective cohort study of participants in pre-FDA approval MT-sDNA studies having nonadvanced or negative baseline colonoscopy findings from a single referral center. Per-protocol and calibrated cutoffs defined FP and TN groups. From the time of stool collection, we measured differences between FP and TN groups in time to death, subsequent cancer diagnosis, and onset of alarm symptoms.
Results: Of 1,050 eligible patients, only 6 were lost to follow-up. Median age was 65.6 years [interquartile range (IQR), 56.8-72.3]; 54% were female. Median follow-up time was 4 years (IQR, 3.5-5.3). Eight aerodigestive (lung and gastrointestinal tract) cancers occurred. FP status by calibrated, but not per-protocol, cutoffs was associated with subsequent aerodigestive cancer; however, cumulative incidence did not exceed SEER expectations from the general population. By any cutoff method, FP status was not associated with mortality or alarm symptoms.Conclusions: Although FP status was associated with long-term aerodigestive cancers, new cases were not temporally related and did not exceed incidence estimates from general population.Impact: These observations do not justify aggressive follow-up evaluation for patients with FP MT-sDNA at this time. Larger studies are needed to confirm these early findings. Cancer Epidemiol Biomarkers Prev; 26(4); 614-21. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27999144      PMCID: PMC5380543          DOI: 10.1158/1055-9965.EPI-16-0800

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  25 in total

1.  How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis.

Authors:  Ulrike Haug; Amy B Knudsen; Karen M Kuntz
Journal:  Int J Cancer       Date:  2012-03-29       Impact factor: 7.396

2.  Next-generation stool DNA test accurately detects colorectal cancer and large adenomas.

Authors:  David A Ahlquist; Hongzhi Zou; Michael Domanico; Douglas W Mahoney; Tracy C Yab; William R Taylor; Malinda L Butz; Stephen N Thibodeau; Linda Rabeneck; Lawrence F Paszat; Kenneth W Kinzler; Bert Vogelstein; Niels Chr Bjerregaard; Søren Laurberg; Henrik Toft Sørensen; Barry M Berger; Graham P Lidgard
Journal:  Gastroenterology       Date:  2011-11-04       Impact factor: 22.682

3.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Ann Intern Med       Date:  2007-10-16       Impact factor: 25.391

4.  Colorectal-cancer incidence and mortality after screening.

Authors:  Reiko Nishihara; Shuji Ogino; Andrew T Chan
Journal:  N Engl J Med       Date:  2013-12-12       Impact factor: 91.245

5.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

6.  Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Karina W Davidson; John W Epling; Francisco A R García; Matthew W Gillman; Diane M Harper; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Douglas K Owens; William R Phillips; Maureen G Phipps; Michael P Pignone; Albert L Siu
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

7.  Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy.

Authors:  Charles J Kahi; David G Hewett; Dustin Lee Norton; George J Eckert; Douglas K Rex
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-01       Impact factor: 11.382

8.  Long-term mortality after screening for colorectal cancer.

Authors:  Aasma Shaukat; Steven J Mongin; Mindy S Geisser; Frank A Lederle; John H Bond; Jack S Mandel; Timothy R Church
Journal:  N Engl J Med       Date:  2013-09-19       Impact factor: 91.245

9.  Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia.

Authors:  Graham P Lidgard; Michael J Domanico; Janelle J Bruinsma; James Light; Zubin D Gagrat; Rebecca L Oldham-Haltom; Keith D Fourrier; Hatim Allawi; Tracy C Yab; William R Taylor; Julie A Simonson; Mary Devens; Russell I Heigh; David A Ahlquist; Barry M Berger
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-29       Impact factor: 11.382

10.  Multitarget stool DNA testing for colorectal-cancer screening.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245

View more
  5 in total

1.  Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing.

Authors:  Gregory S Cooper; Sanford D Markowitz; Zhengyi Chen; Missy Tuck; Joseph E Willis; Barry M Berger; Dean E Brenner; Li Li
Journal:  Dig Dis Sci       Date:  2018-03-07       Impact factor: 3.199

2.  Polyp Resection and Removal Procedures: Insights From the 2017 Digestive Disease Week.

Authors:  Carol Burke; Vivek Kaul; Heiko Pohl
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-09

Review 3.  Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance.

Authors:  Jason D Eckmann; Derek W Ebner; John B Kisiel
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-21

Review 4.  Current and future colorectal cancer screening strategies.

Authors:  Aasma Shaukat; Theodore R Levin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-05-03       Impact factor: 73.082

5.  Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study.

Authors:  Jianping Wang; Side Liu; Hui Wang; Lei Zheng; Changchun Zhou; Guoxin Li; Rongkang Huang; Huaiming Wang; Chujun Li; Xinjuan Fan; Xinhui Fu; Xinying Wang; Hongliang Guo; Jie Guan; Yanlai Sun; Xilin Song; Zengjun Li; Dianbin Mu; Jujie Sun; Xianglin Liu; Yan Qi; Feng Niu; Chunhua Chen; Xiaolin Wu; Xianshu Wang; Xianrang Song; Hongzhi Zou
Journal:  Clin Epigenetics       Date:  2020-10-30       Impact factor: 6.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.